Navoximod; 1402837-78-8; IDO-IN-7; GDC-0919; Navoximod [USAN]; Navoximod (free base); NLG-919; 926SHL95NC; RO7077339-001; RG6078; RG-6078; RO7077339; RO-7077339; 4-[(1R)-2-[(5S)-6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl]-1-hydroxyethyl]cyclohexan-1-ol; trans-4-{(1R)-2-[(5S)-6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl]-1-hydroxyethyl}cyclohexan-1-ol; NLG-919 Navoximod; NAVOXIMOD [INN]; Navoximod (USAN/INN); NAVOXIMOD [WHO-DD]; UNII-926SHL95NC; CHEMBL3989951; CHEMBL4530496; SCHEMBL13469854; SCHEMBL13469866; SCHEMBL15511408; BDBM370551; BDBM370555; EX-A4607; NLG-?919; NLG-?919GDC-0919; HY-18770B; s8957; ZINC253387955; CS-5088; DB15439; US10233190, Example 1484; US10233190, Example 1488; AC-35763; D11255; F85292; Navoximod;GDC-0919;IDO-IN-7;NLG-1488; Q27271481; (1R,4r)-4-((R)-2-((S)-6-fluoro-5H-imidazo[5,1- a]isoindol-5-yl)-1-hydroxyethyl)cyclohexanol; (1S,4s)-4-((R)-2-((S)-6-fluoro-5H-imidazo[5,1- a]isoindol-5-yl)-1-hydroxyethyl)cyclohexanol; 1402836-86-5; 5H-IMIDAZO(5,1-A)ISOINDOLE-5-ETHANOL, 6-FLUORO-.ALPHA.-(TRANS-4-HYDROXYCYCLOHEXYL)-, (.ALPHA.R,5S)-; 5H-Imidazo(5,1-a)isoindole-5-ethanol, 6-fluoro-alpha-(trans-4-hydroxycyclohexyl)-, (alphaR,5S)-; Trans-4-((1R)-2-((5S)-6-Fluoro-5H-imidazo(5,1-a)isoindol-5-yl)-1-hydroxyethyl)cyclohexanol